

Cimdelirsén sodium

Cat. No.:	HY-153485A
CAS No.:	2131025-83-5
Molecular Formula:	C ₂₉₆ H ₄₁₅ N ₈₃ Na ₂₀ O ₁₅₂ P ₂₀ S ₁₅
Molecular Weight:	9128.16
Target:	Small Interfering RNA (siRNA)
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Cimdelirsén (sodium)

BIOLOGICAL ACTIVITY

Description

Cimdelirsén is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHR) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

REFERENCES

[1]. Bhanot S, Fleseriu M, Geary R, et al. OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsén (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients. *J Endocr Soc.* 2022;6(Suppl 1):A526.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA